Hepatitis B Surface Antigen Positivity is An Independent Unfavorable Prognostic Factor in Diffuse Large B-cell Lymphoma in The Rituximab Era.
暂无分享,去创建一个
T. Su | Jia-Hong Chen | H. Tien | W. Fang | Jia-Hau Liu | Chang-Tsu Yuan | Chieh-Lung Cheng | Sheng-Chuan Huang | M. Chuang | Chao-Hung Wei
[1] D. Carrick,et al. The Impact: , 2020, Call My Name, Clemson.
[2] Ding‐Shinn Chen,et al. Chronic hepatitis B is associated with an increased risk of B‐cell non‐Hodgkin's lymphoma and multiple myeloma , 2019, Alimentary pharmacology & therapeutics.
[3] C. Fan,et al. Hepatitis B virus and risk of non‐Hodgkin lymphoma: An updated meta‐analysis of 58 studies , 2018, Journal of viral hepatitis.
[4] Kui Wu,et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. , 2018, Blood.
[5] Mubarak M. Al-Mansour,et al. Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma , 2018, Infectious Agents and Cancer.
[6] Hui Zheng,et al. Capable Infection of Hepatitis B Virus in Diffuse Large B-cell Lymphoma , 2018, Journal of Cancer.
[7] Q. Mu,et al. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes , 2018, Journal of cancer research and therapeutics.
[8] Jianmin Yang,et al. HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma , 2018, Cell Death & Disease.
[9] W. Guo,et al. MYC Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection , 2017, BioMed research international.
[10] W. Guo,et al. PD1 is highly expressed in diffuse large B-cell lymphoma with hepatitis B virus infection , 2017, PloS one.
[11] K. Young,et al. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin , 2015, Oncotarget.
[12] R. Greil,et al. A modified scoring of the NCCN‐IPI is more accurate in the elderly and is improved by albumin and β2‐microglobulin , 2015, British journal of haematology.
[13] R. Gascoyne,et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. , 2014, Blood.
[14] Junmin Li,et al. HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China , 2014, Medical Oncology.
[15] Chiun Hsu,et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. , 2013, European journal of cancer.
[16] J. Castillo,et al. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. , 2013, Leukemia research.
[17] He Huang,et al. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy , 2013, Experimental and therapeutic medicine.
[18] T. Habermann,et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma , 2011, Leukemia.
[19] S. Kimura,et al. Reactivation of hepatitis B virus after rituximab‐containing treatment in patients with CD20‐positive B‐cell lymphoma , 2010, Cancer.
[20] B. Coiffier,et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.
[21] S. Jee,et al. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. , 2010, The Lancet. Oncology.
[22] G. Weiner,et al. Rituximab: mechanism of action. , 2010, Seminars in hematology.
[23] Chien-Hung Chen,et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients , 2010, Annals of Hematology.
[24] P. Pontisso,et al. Biological and clinical implications of HBV infection in peripheral blood mononuclear cells. , 2008, Autoimmunity reviews.
[25] Wen-Qi Jiang,et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma , 2008, BMC Cancer.
[26] L. Ruco,et al. Absolute lymphocyte count is a prognostic factor in diffuse large B‐cell lymphoma , 2008, British journal of haematology.
[27] Ming-Huang Chen,et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma , 2008, Annals of Hematology.
[28] S. Lim,et al. The relationship of hepatitis B virus infection and non‐Hodgkin’s lymphoma and its impact on clinical characteristics and prognosis , 2007, European journal of haematology.
[29] Y. Chae,et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma , 2007, Leukemia.
[30] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Randy D Gascoyne,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] R. Gascoyne,et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] H. Seno,et al. Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers. , 2005, Journal of hepatology.
[34] S. Markovic,et al. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation , 2004, Clinical and Experimental Medicine.
[35] Ding-Shinn Chen,et al. Global control of hepatitis B virus infection. , 2002, The Lancet. Infectious diseases.
[36] Y. Bang,et al. Hepatitis B Virus Infection and B‐Cell Non‐Hodgkin's Lymphoma in a Hepatitis B Endemic Area: A Case‐control Study , 2002, Japanese journal of cancer research : Gann.
[37] H. Hsu,et al. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: A study just before mass hepatitis B vaccination program in Taiwan , 1986, Journal of medical virology.
[38] S. Yip,et al. The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma. , 2015, European journal of cancer care.
[39] E. Iannitto,et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. , 2006, Haematologica.
[40] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.